#Immunotherapy is an active hashtag on Bluesky. In the last 30 days, 77 people shared 149 posts with it — around 5 a day. Activity is up 3% versus the previous week, peaking on Jul 27 with 11 posts.
Tags most often used together with #Immunotherapy.
www.science.org
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function
Modulation of exhausted CD8+ T cell differentiation by targeting TET2 improves therapeutic potential of CAR T cells in cancer.
www.nature.com
Keeping the immuno-oncology flame burning
Ira Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy, asks why so many drug developers are retreating from immune-modulating drugs, cell therapies and cancer vac...
www.the-scientist.com
Why Are Breast Cancers That Metastasize to the Brain Hard to Treat?
Immunosuppressive factors prevent killer T cells from defeating brain tumors that arise from primary breast cancer.
www.embopress.org
Interferon-induced PARP14-mediated ADP-ribosylation in p62 bodies requires the ubiquitin-proteasome system | The EMBO Journal
imageimageInterferon induces the formation of ADP-ribosylation (ADPr)-enriched p62 bodies, requiring PARP14 and p62. Unlike canonical p62 bodies, these ADPr-enriched structures are independent of auto...
www.cell.com
Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation
The serine/glycine-free diet inhibits CRC growth and enhances antitumor immunity but also promotes immune evasion through PD-L1 lactylation. It shows promise when combined with immunotherapy and has been proven feasible and safe in a single-arm, phase I trial.
The Innovation | Medicine @innovationmedicine.bsky.social
The serine/glycine-free diet, like Athena’s dual approach in warfare, boosts tumor visibility (MHC-I) while inducing PD-L1 lactylation as a shield. PD-1 inhibitors, akin to Athena’s wisdom, neutralize this defense, enabling immune attack. Clinical trials confirm its promising synergy.
scim.ag
Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1
mTORC1 activation by components of a cytokine cocktail enhances NK cell cytotoxicity toward cancer cells.
www.cell.com
The local microenvironment suppresses the synergy between irradiation and anti-PD1 therapy in breast-to-brain metastasis
Wischnewski et al. demonstrate suppressed CD8+ T cell cytotoxicity in breast cancer brain metastases, contrasting with genetically identical extracranial tumors. Neutrophils and Trem2+ macrophages dri...
www.onclive.com
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer | OncLive
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
www.medicaldaily.com
UCLA Wins $3.9 Million to Test Drugs That Might Make Melanoma Immunotherapy Work for More Patients
UCLA received a $3.9M NCI grant to test two compounds aimed at making melanoma immunotherapy work in more patients. What the funding does and does not cover.
doi.org
Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers
Statement of Significance We developed two novel complementary therapeutic modalities targeting an emerging gastrointestinal tumor-associated antigen, CDH1
doi.org
Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform
Statement of Significance: We discovered a common light chain (CLC) bispecific antibody targeting PD-1 and PD-L1 with favorable biophysical properties and
dlvr.it
ASCO GI 2025 SoMe Report.pdf
Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.
news.utexas.edu
Cancer Drug Restores Immune System’s Ability to Fight Tumors
AUSTIN, Texas — A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of
news.utexas.edu
Experimental Chemo Drug May Trick the Immune System Into Fighting Cancer
The findings suggest that inducing viral mimicry could not only boost immune attacks on tumors but also reduce chemotherapy doses and limit drug resistance over time.
www.jpost.com
TAU researchers identify immune process that may fuel cancer growth | The Jerusalem Post
The research focused on macrophages, immune cells responsible for removing damaged and dead cells from the body.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.
